Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway
This study elucidates the role of the PRDX2/SP1/FN1 axis in TNBC migration and invasion, and highlights PRDX2 as a promising therapeutic target for triple-negative breast cancer.
Authors
- Li Xuan (ORCID: https://orcid.org/0000-0002-6176-7411)
- Yafeng Liu (ORCID: https://orcid.org/0000-0003-3930-4872)
- Anqi Cheng (ORCID: https://orcid.org/0000-0003-3232-3683)
- Dong Hu (ORCID: https://orcid.org/0000-0003-4435-2131)
- Jiawei Zhou (ORCID: https://orcid.org/0000-0002-1844-9178)
- Jing Wu (ORCID: https://orcid.org/0009-0007-3183-8972)
- Jianqiang Guo (ORCID: https://orcid.org/0009-0007-4517-5524)
- Maoqian Chen
Institutions
- University of Science and Technology of China (CN)
- Anhui University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1186/s12967-025-06441-2
- Citations
- 10
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 8.06
Funders
- National Natural Science Foundation of China
- Anhui University
- Anhui University of Science and Technology